الاريثؤوبيوتين (الهرمون المكون للدم ), مصل , بلازما

EPO, produced mainly by peritubular interstitial cells in the kidney, acts as a major regulator of erythropoiesis, by promoting the survival and proliferation of erythroid precursor cells. EPO acts primarily on apoptosis to decrease the rate of cell death in erythroid progenitor cells in the bone marrow. EPO can also exert non-erythropoietic effects. Recent evidence suggests that the administration of recombinant human-EPO plays a protective role in vascular diseases.

Increased EPO levels are found in patients with tissue hypoxia including anaemia, lung disease, or cyanotic heart disease and chronic heart failure. In anaemia, serum EPO levels do not rise above normal until Haemoglobin levels fall below 110 g/L. Decreased levels are seen inpatients with renal insufficiency, anaemic patients with cancer, as well as those with rheumatoid arthritis, HIV infection, ulcerative colitis, sickle cell anaemia, and the anaemia of prematurity.

1 ml Serum Room Temperature

Avoid grossly haemolysed or grossly lipemic samples. Avoid repeated freeze/thaw cycles.

3.22-31.9 mIU/mL